A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open‐label parallel study

Sathyapalan, Thozhukat; Cho, Li Wei; Kilpatrick, Eric S.; Coady, Anne‐Marie; Atkin, Stephen L.

doi:10.1111/j.1365-2265.2008.03260.x

Cited by 29 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a comparison of rimonabant (20 mg/daily) and metformin (1500 mg daily) in obese women with PCOS, rimonabant significantly reduced body weight, waist circumference, hyperandrogenism, and insulin resistance with no changes in these parameters reported for metformin. These promising preliminary data support the need for further randomized large studies on CB1-antogonists in obese PCOS women (92). An additional future area of interest is the use of metformin, an insulin sensitizer, in weight management.…”

Section: Pharmacologic Treatmentmentioning

confidence: 82%

Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society

Moran

Pasquali

Teede

et al. 2009

Fertility and Sterility

354

284

View full text Add to dashboard Cite

Section: Pharmacologic Treatmentmentioning

confidence: 82%

Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society

Moran

Pasquali

Teede

et al. 2009

Fertility and Sterility

354

284

View full text Add to dashboard Cite

“…Recently, rimonabant was used in a randomized trial with metformin in 20 women with PCOS. Body weight, insulin resistance, and testosterone levels decreased after rimonabant, but not after metformin [143]. However, one of the unwanted side effects of cannabinoid receptor blockers is depression, which was reported in 26% of subjects given 20 mg of rimonabant [144].…”

Section: Depression Health-related Quality Of Life and Polycystic Ovmentioning

confidence: 99%

Obesity and Polycystic Ovary Syndrome

Vrbíková¹,

Hainer²

2009

Obes Facts

163

102

View full text Add to dashboard Cite

“…For the second biological variability study, clinical and biochemical assessments were performed at each visit on 10 consecutive occasions at 4-day intervals before and 12-weeks after treatment [12]. …”

Section: Methodsmentioning

confidence: 99%

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundEvidence suggests that endocannabinoid system activation through the cannabinoid receptor 1 (CB1) is associated with enhanced liver injury, and CB1 antagonism may be beneficial. The aim of this study was to determine the impact of rimonabant (CB1 antagonist) on alanine aminotransferase (ALT), a hepatocellular injury marker, and a hepatic inflammatory cytokine profile.MethodsPost hoc review of 2 studies involving 50 obese women with PCOS and well matched for weight, randomised to weight reducing therapy; rimonabant (20 mg od) or orlistat (120 mg tds), or to insulin sensitising therapy metformin, (500 mg tds), or pioglitazone (45 mg od). No subject had non-alcoholic fatty liver disease (NAFLD).ResultsTreatment with rimonabant for 12 weeks reduced both ALT and weight (p < 0.01), and there was a negative correlation between Δ ALT and Δ HOMA-IR (p < 0.001), but not between Δ ALT and Δ weight. There was a significant reduction of weight with orlistat (p < 0.01); however, orlistat, metformin and pioglitazone had no effect on ALT. The free androgen index fell in all groups (p < 0.05). The inflammatory marker hs-CRP was reduced by pioglitazone (p < 0.001) alone and did not correlate with changes in ALT. The inflammatory cytokine profile for IL-1β, IL-6, IL-7, IL-10, IL12, TNF-α, MCP-1 and INF-γ did not differ between groups. None of the interventions had an effect on biological variability of ALT.ConclusionRimonabant through CB1 receptor blockade decreased serum ALT that was independent of weight loss and hepatic inflammatory markers in obese women with PCOS without NAFLD.Trial registrationISRCTN58369615 (February 2007; retrospectively registered) ISRCTN75758249 (October 2007; retrospectively registered).

show abstract

A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open‐label parallel study

Abstract: This study suggests that the weight loss through rimonabant therapy may be of use in patients with PCOS and appears superior to insulin sensitization by metformin in reducing the FAI and insulin resistance in obese PCOS patients treated over a 12-week period.

Cited by 29 publications

References 34 publications

Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society

Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society

Obesity and Polycystic Ovary Syndrome

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

Contact Info

Product

Resources

About